Literature DB >> 7897410

Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events.

M Trojano1, C Avolio, C Manzari, A Calò, F De Robertis, G Serio, P Livrea.   

Abstract

The clinical data of 309 patients with definite multiple sclerosis were recorded in the European data base for multiple sclerosis (EDMUS) to determine the prognostic significance of several demographic and clinical variables. An interview with closed questions structured according to standardised criteria of disease phases and courses was used to assess the clinical course. The reliability was evaluated by four trained neurologists in a sample of 33 patients with multiple sclerosis. Both the within and between rater agreement on data collection was fair to high for the historical variables (K = 0.33-1). Between rater agreement was more variable for the evaluation of 12 different EDMUS event categories (K = 0.3-0.95). The predictive model for the time to reach a secondary progression showed that an age at onset older than 25 (p = 0.006) and an event at onset followed by disability > or = 3 on the Kurtzke expanded disability status scale (EDSS; p = 0.004) were the most unfavourable clinical variables in 249 patients with relapsing remitting (180) or relapsing progressive (69) courses. In the 69 patients with relapsing progressive disease, the time to reach severe disability (EDSS > or = 6) was negatively influenced by a first interval between attacks shorter than one year, a number of bouts with EDSS > 2 in the first two years of the disease, and involvement of the pyramidal system at onset (p < 0.05). In 60 patients with chronic progressive disease this outcome was negatively influenced by pyramidal, brainstem, and sensory involvement at onset (p < 0.01).

Entities:  

Mesh:

Year:  1995        PMID: 7897410      PMCID: PMC1073365          DOI: 10.1136/jnnp.58.3.300

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  30 in total

1.  CLINICAL STUDIES OF MULTIPLE SCLEROSIS IN ISRAEL. 3. CLINICAL COURSE AND PROGNOSIS RELATED TO AGE AT ONSET.

Authors:  U LEIBOWITZ; M ALTER; L HALPERN
Journal:  Neurology       Date:  1964-10       Impact factor: 9.910

2.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

3.  The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-12       Impact factor: 13.501

4.  A clinical and laboratory study of benign multiple sclerosis.

Authors:  A J Thompson; M Hutchinson; J Brazil; C Feighery; E A Martin
Journal:  Q J Med       Date:  1986-01

5.  Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study.

Authors:  J M Minderhoud; J H van der Hoeven; A J Prange
Journal:  Acta Neurol Scand       Date:  1988-07       Impact factor: 3.209

6.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-02       Impact factor: 13.501

7.  Clinical studies on multiple sclerosis. I. Presentation of an incidence material from Gothenburg.

Authors:  T Broman; O Andersen; L Bergmann
Journal:  Acta Neurol Scand       Date:  1981-01       Impact factor: 3.209

8.  Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials.

Authors:  D E Goodkin; D Hertsgaard; R A Rudick
Journal:  Arch Neurol       Date:  1989-10

9.  The natural history of multiple sclerosis: a regional study with some longitudinal data.

Authors:  D H Miller; R W Hornabrook; G Purdie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-05       Impact factor: 10.154

10.  Multiple sclerosis after age 50.

Authors:  J Noseworthy; D Paty; T Wonnacott; T Feasby; G Ebers
Journal:  Neurology       Date:  1983-12       Impact factor: 9.910

View more
  24 in total

1.  Relapses and disability accumulation in progressive multiple sclerosis.

Authors:  M Mateo Paz Soldán; Martina Novotna; Nuhad Abou Zeid; Nilufer Kale; Melih Tutuncu; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; B Mark Keegan; Istvan Pirko; Sean J Pittock; Claudia F Lucchinetti; Brian G Weinshenker; Moses Rodriguez; Orhun H Kantarci
Journal:  Neurology       Date:  2014-11-14       Impact factor: 9.910

2.  Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

Authors:  Valentina Tomassini; Andrea Paolillo; Pierluigi Russo; Elisabetta Giugni; Luca Prosperini; Claudio Gasperini; Guido Antonelli; Stefano Bastianello; Carlo Pozzilli
Journal:  J Neurol       Date:  2005-09-14       Impact factor: 4.849

3.  European validation of a standardized clinical description of multiple sclerosis.

Authors:  Maria Pia Amato; Jerome Grimaud; Iuliana Achiti; Maria Letizia Bartolozzi; Patrice Adeleine; Hans-Peter Hartung; Ludwig Kappos; Alan Thompson; Maria Trojano; Sandra Vukusic; Christian Confavreux
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

4.  Clinical characteristics and long term prognosis in early onset multiple sclerosis.

Authors:  Olivier Deryck; Pierre Ketelaer; Bénédicte Dubois
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

Review 5.  Multiple sclerosis in the elderly patient.

Authors:  Amer Awad; Olaf Stüve
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

Review 6.  Aggressive multiple sclerosis: proposed definition and treatment algorithm.

Authors:  Carolina A Rush; Heather J MacLean; Mark S Freedman
Journal:  Nat Rev Neurol       Date:  2015-06-02       Impact factor: 42.937

7.  Clinical, CSF, and MRI findings in Devic's neuromyelitis optica.

Authors:  J I O'Riordan; H L Gallagher; A J Thompson; R S Howard; D P Kingsley; E J Thompson; W I McDonald; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-04       Impact factor: 10.154

8.  Clinical characteristics of patients with late-onset multiple sclerosis.

Authors:  Bernhard Kis; Bastian Rumberg; Peter Berlit
Journal:  J Neurol       Date:  2008-02-19       Impact factor: 4.849

9.  Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis.

Authors:  C L Hirst; A Pace; T P Pickersgill; R Jones; B N McLean; J P Zajicek; N J Scolding; N P Robertson
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

10.  Relation between EDSS and monosymptomatic or polysymptomatic onset in clinical manifestations of multiple sclerosis in Babol, northern Iran.

Authors:  Seyed Mohammad Masood Hojjati; Seyyed Ali Hojjati; Mobina Baes; Ali Bijani
Journal:  Caspian J Intern Med       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.